Simulations Plus (NASDAQ:SLP) Announces Earnings Results, Beats Expectations By $0.06 EPS

Simulations Plus (NASDAQ:SLP) issued its quarterly earnings results on Thursday. The technology company reported $0.31 earnings per share for the quarter, topping the consensus estimate of $0.25 by $0.06, Zacks reports. Simulations Plus had a net margin of 10.97% and a return on equity of 6.84%. The company had revenue of $22.43 million for the quarter, compared to the consensus estimate of $21.93 million. During the same quarter in the prior year, the company earned $0.20 EPS. Simulations Plus’s quarterly revenue was up 22.5% on a year-over-year basis. Simulations Plus updated its FY25 guidance to $1.07-1.20 EPS.

Simulations Plus Price Performance

SLP stock traded down $0.95 during trading on Thursday, hitting $23.82. The stock had a trading volume of 351,146 shares, compared to its average volume of 175,219. The company’s 50-day moving average price is $30.38 and its two-hundred day moving average price is $30.38. Simulations Plus has a twelve month low of $23.00 and a twelve month high of $51.22. The stock has a market capitalization of $478.59 million, a P/E ratio of 59.55 and a beta of 0.89.

Analysts Set New Price Targets

SLP has been the subject of several recent research reports. William Blair reissued an “outperform” rating on shares of Simulations Plus in a report on Wednesday, January 8th. KeyCorp raised their target price on Simulations Plus from $35.00 to $37.00 and gave the company an “overweight” rating in a research report on Friday, January 24th. One analyst has rated the stock with a sell rating, one has issued a hold rating, five have given a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat.com, Simulations Plus presently has a consensus rating of “Moderate Buy” and an average price target of $49.40.

Insider Activity

In other news, Director Walter S. Woltosz sold 20,000 shares of the company’s stock in a transaction on Monday, February 3rd. The shares were sold at an average price of $33.91, for a total transaction of $678,200.00. Following the completion of the sale, the director now owns 3,402,584 shares of the company’s stock, valued at $115,381,623.44. This represents a 0.58 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Company insiders own 19.40% of the company’s stock.

About Simulations Plus

Simulations Plus, Inc develops drug discovery and development software for modeling and simulation, and prediction of molecular properties utilizing artificial intelligence and machine learning based technology worldwide. The company operates through two segments, Software and Services. It offers GastroPlus, which simulates the absorption and drug interaction of compounds administered to humans and animals; and DDDPlus and MembranePlus simulation products.